The company's lead product candidate, lenabasum, is an oral drug designed to resolve chronic inflammation and fibrotic processes. It is currently being evaluated for various diseases such as systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. Corbus also has a pipeline of over 600 compounds targeting the endocannabinoid system, including CRB-4001, a potential treatment for NASH. The company plans to start a Phase 1 study of CRB-4001 in 2019, followed by a Phase 2 study funded by the National Institutes of Health. Corbus Pharmaceuticals aims to develop innovative medicines to address unmet needs in inflammatory, fibrotic, metabolic, and cancer-related diseases.